Autoimmune Gastrointestinal Dysmotility Market Size to Exceed $2.3 Billion by 2029 | Growth and Industry Trends
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Autoimmune Gastrointestinal Dysmotility Market Grown from 2024 to 2025?#_x000D_
Over the years, the autoimmune gastrointestinal dysmotility market has shown remarkable growth. It is projected that this market will expand from $1.73 billion in 2024 to $1.83 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.0%. The considerable growth during the historic period is due to factors such as limited awareness of rare diseases, the pervasiveness of underdeveloped diagnostic methods, an increasing number of misdiagnoses with other GI disorders, lack of targeted therapies, and significant research delays._x000D_
_x000D_
#What Growth Rate Is Anticipated for the Autoimmune Gastrointestinal Dysmotility Market in the Coming Years?#_x000D_
There is a positive outlook for the autoimmune gastrointestinal dysmotility market in the upcoming years, with the projection of its growth to $2.30 billion by 2029. The CAGR is estimated at 5.9%. This anticipated market expansion is due to factors such as increased prevalence of autoimmune diseases, advancements in diagnosis methods, upsurged healthcare expenditure, growth of rare disease registries, and improved clinicians’ education. Key trends for this period encompass advancements in diagnostic technology, progress in immunotherapy, expansion of neurogastroenterology research, development in motility modulators, and adoption of individualized treatment strategies._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp_x000D_
_x000D_
#Who Are the Leading Companies in the Autoimmune Gastrointestinal Dysmotility Market?#_x000D_
Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc._x000D_
_x000D_
#What Are the Key Drivers of the Autoimmune Gastrointestinal Dysmotility Market?#_x000D_
The escalating occurrence of autoimmune diseases is anticipated to spur the expansion of the autoimmune gastrointestinal dysmotility market. In autoimmune diseases, the body’s immune system mistakenly combats its own healthy cells, tissues, or organs rather than safeguarding them against infections and alien substances. The increase in autoimmune diseases chiefly stems from both genetic vulnerability and external triggers which collectively disturb the immune system’s regulation, enhancing the odds of the body’s own tissues getting attacked. Autoimmune gastrointestinal dysmotility assists in recognising and managing autoimmune diseases by showing the immune-caused harm to the enteric nervous system and connecting gastrointestinal symptoms to systemic autoimmune actions. For instance, as per a survey by Versorgungsatlas.de, a German organization in November 2024, around 6,304,340 out of 73,241,305 in 2022 were diagnosed with a minimum of one autoimmune disease, which resulted in a crude prevalence rate of 8.61. Hence, the increasing occurrence of autoimmune diseases is fuelling the growth of the autoimmune gastrointestinal dysmotility market. The growing concentration on personalized medicine is anticipated to propel the expansion of the autoimmune gastrointestinal dysmotility market. Personalized medicine is a medical method that customizes prevention tactics and treatment based on a person’s unique genetic constitution, lifestyle, and surroundings. The emergence of personalized medicine is predominantly due to advancements in genomics, which facilitates the explicit identification of genetic variations and custom treatments for individuals. Personalized medicine aids in treating autoimmune gastrointestinal dysmotility by modifying therapies concerning an individual’s genetic makeup and specific disease features, thereby improving treatment success and reducing side effects, offering more focused solutions for managing complicated gastrointestinal disorders. For instance, the U.S Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a substantial rise from the 12 sanctioned in 2022, according to the Personalized Medicine Coalition (PMC), a US nonprofit organization, in February 2024. Hence, the increased concentration on personalized medicine is fuelling the growth of the autoimmune gastrointestinal dysmotility market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp_x000D_
_x000D_
#What Are the Key Market Segments in the Autoimmune Gastrointestinal Dysmotility Industry?#_x000D_
The autoimmune gastrointestinal dysmotility market covered in this report is segmented –_x000D_
_x000D_
1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy_x000D_
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics_x000D_
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease_x000D_
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels_x000D_
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions_x000D_
_x000D_
Subsegments:_x000D_
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics_x000D_
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy_x000D_
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals_x000D_
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training_x000D_
_x000D_
#What Are the Latest Trends in the Autoimmune Gastrointestinal Dysmotility Market?#_x000D_
Major firms in the autoimmune gastrointestinal dysmotility market are strategically partnering to offer digital therapeutic solutions for the condition. These alliances enhance the autoimmune gastrointestinal dysmotility care, providing integrated virtual-based health services, boosting symptom management, accessibility, and cost-effectiveness. A case in point is the partnership formed in March 2022 between Solera Health, a digital health organization from the United States, Oshi Health, a U.S. virtual gastrointestinal care firm, and Vivante Health, another U.S.-based digital health firm. Their joint effort aims to deliver sophisticated digital treatment options for managing and treating autoimmune gastrointestinal dysmotility. The partnership is designed to increase access to specialized care and heighten overall treatment efficiency for those dealing with gastrointestinal disorders._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#What Are the Key Regional Markets in the Autoimmune Gastrointestinal Dysmotility Industry?#_x000D_
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=24160&type=smp_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the autoimmune gastrointestinal dysmotility market, and how is it changing globally?_x000D_
2. Who are the major companies in the autoimmune gastrointestinal dysmotility market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the autoimmune gastrointestinal dysmotility market right now?_x000D_
4. Which products or customer segments are growing the most in the autoimmune gastrointestinal dysmotility market?_x000D_
5. What factors are helping or slowing down the growth of the autoimmune gastrointestinal dysmotility market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Europe +44 7882 955267_x000D_
Asia & Others +44 7882 955267 & +91 8897263534_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
